[{"id":"cf2cfcd4-c077-4397-9d63-381c2282ddc5","acronym":"TATCIST","url":"https://clinicaltrials.gov/study/NCT05219500","created_at":"2022-02-05T18:28:39.147Z","updated_at":"2025-02-25T15:12:35.305Z","phase":"Phase 2","brief_title":"Targeted Alpha Therapy with 225Actinium-Prostate Specific Membrane Antigen (PSMA)-I\u0026T of Castration-resISTant Prostate Cancer (TATCIST).","source_id_and_acronym":"NCT05219500 - TATCIST","lead_sponsor":"Fusion Pharmaceuticals Inc.","biomarkers":" MSI • BRCA","pipe":" | ","alterations":" BRCA mutation","tags":["MSI • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FPI-2265"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 115","initiation":"Initiation: 12/16/2021","start_date":" 12/16/2021","primary_txt":" Primary completion: 04/30/2025","primary_completion_date":" 04/30/2025","study_txt":" Completion: 07/31/2025","study_completion_date":" 07/31/2025","last_update_posted":"2025-02-13"},{"id":"791ed3e1-159a-4669-b6a9-9650c77c7e2f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05079698","created_at":"2021-10-15T14:53:06.706Z","updated_at":"2025-02-25T15:54:10.535Z","phase":"Phase 1","brief_title":"A Study of Stereotactic Body Radiotherapy and 177Lu-PSMA-617 for the Treatment of Prostate Cancer","source_id_and_acronym":"NCT05079698","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" EGFR","pipe":"","alterations":" ","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Pluvicto (lutetium Lu 177 vipivotide tetraxetan)"],"overall_status":"Recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 10/01/2021","start_date":" 10/01/2021","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 10/01/2025","study_completion_date":" 10/01/2025","last_update_posted":"2025-01-03"},{"id":"5b3663eb-53d2-4913-aef6-1eb4ef0d39c4","acronym":"","url":"https://clinicaltrials.gov/study/NCT06084338","created_at":"2023-10-16T15:12:50.854Z","updated_at":"2025-02-25T17:39:27.404Z","phase":"Phase 2","brief_title":"Randomized Phase II Trial of Targeted Radiation With no Castration for Mcrpc","source_id_and_acronym":"NCT06084338","lead_sponsor":"VA Office of Research and Development","biomarkers":" EGFR","pipe":"","alterations":" ","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Pluvicto (lutetium Lu 177 vipivotide tetraxetan)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 12/14/2023","start_date":" 12/14/2023","primary_txt":" Primary completion: 11/29/2027","primary_completion_date":" 11/29/2027","study_txt":" Completion: 12/31/2028","study_completion_date":" 12/31/2028","last_update_posted":"2024-12-30"},{"id":"8247cdb4-7bc6-434e-8424-d805cacb6db9","acronym":"LuCAB","url":"https://clinicaltrials.gov/study/NCT05340374","created_at":"2022-04-22T14:53:47.311Z","updated_at":"2025-02-25T17:37:46.899Z","phase":"Phase 1/2","brief_title":"Cabazitaxel in Combination With 177Lu-PSMA-617 in Metastatic Castration-resistant Prostate Cancer","source_id_and_acronym":"NCT05340374 - LuCAB","lead_sponsor":"Peter MacCallum Cancer Centre, Australia","biomarkers":" AR","pipe":"","alterations":" ","tags":["AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • cabazitaxel • Pluvicto (lutetium Lu 177 vipivotide tetraxetan)"],"overall_status":"Recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 07/14/2022","start_date":" 07/14/2022","primary_txt":" Primary completion: 06/20/2026","primary_completion_date":" 06/20/2026","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-11-08"},{"id":"14077522-c4f9-49b8-a790-5ed5d6ceade7","acronym":"","url":"https://clinicaltrials.gov/study/NCT04928612","created_at":"2025-03-03T15:59:29.814Z","updated_at":"2025-03-03T15:59:29.814Z","phase":"Phase 1","brief_title":"A Study of CBP-1018 in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT04928612","lead_sponsor":"Coherent Biopharma (Suzhou) Co., Ltd.","biomarkers":" FOLR1","pipe":"","alterations":" ","tags":["FOLR1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CBP-1018"],"overall_status":"Recruiting","enrollment":" Enrollment 170","initiation":"Initiation: 11/04/2021","start_date":" 11/04/2021","primary_txt":" Primary completion: 10/01/2024","primary_completion_date":" 10/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-08-28"},{"id":"3a3871a3-373b-4120-a2fd-01f883ff6944","acronym":"","url":"https://clinicaltrials.gov/study/NCT06066437","created_at":"2023-10-04T15:10:45.245Z","updated_at":"2024-07-02T16:35:12.192Z","phase":"Phase 1/2","brief_title":"NeoAdjuvant Theranostic Lutetium Study: The Nautilus Trial","source_id_and_acronym":"NCT06066437","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" FOLH1","pipe":" | ","alterations":" FOLH1 expression","tags":["FOLH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FOLH1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Firmagon (degarelix)"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 03/29/2024","start_date":" 03/29/2024","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2024-04-01"},{"id":"20bf54e0-4880-4089-bf7e-5fd51d6f7aee","acronym":"VIOLET","url":"https://clinicaltrials.gov/study/NCT05521412","created_at":"2022-08-30T20:55:59.611Z","updated_at":"2024-07-02T16:35:14.372Z","phase":"Phase 1/2","brief_title":"EValuation of radIOLigand Treatment in mEn With Metastatic Castration-resistant Prostate Cancer With [161Tb]Tb-PSMA-I\u0026T","source_id_and_acronym":"NCT05521412 - VIOLET","lead_sponsor":"Peter MacCallum Cancer Centre, Australia","biomarkers":" AR","pipe":"","alterations":" ","tags":["AR"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 09/29/2022","start_date":" 09/29/2022","primary_txt":" Primary completion: 08/03/2024","primary_completion_date":" 08/03/2024","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-03-18"},{"id":"1bc7d467-7896-491d-8c0c-8c4bb935a5f1","acronym":"","url":"https://clinicaltrials.gov/study/NCT03972657","created_at":"2023-08-08T17:08:39.649Z","updated_at":"2024-07-02T16:35:15.522Z","phase":"Phase 1/2","brief_title":"A Trial to Find Out if REGN5678 is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors","source_id_and_acronym":"NCT03972657","lead_sponsor":"Regeneron Pharmaceuticals","biomarkers":" FOLH1","pipe":" | ","alterations":" FOLH1 expression","tags":["FOLH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FOLH1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Libtayo (cemiplimab-rwlc) • Kevzara (sarilumab) • nezastomig (REGN5678)"],"overall_status":"Recruiting","enrollment":" Enrollment 345","initiation":"Initiation: 08/12/2019","start_date":" 08/12/2019","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 07/03/2026","study_completion_date":" 07/03/2026","last_update_posted":"2024-03-08"},{"id":"37ba8d01-7c78-43cc-81e1-59e78827f9d6","acronym":"","url":"https://clinicaltrials.gov/study/NCT04367675","created_at":"2021-01-18T21:06:34.302Z","updated_at":"2024-07-02T16:35:32.189Z","phase":"Phase 1b","brief_title":"INO 5401 Vaccination in BRCA1/2 Mutation Carriers","source_id_and_acronym":"NCT04367675","lead_sponsor":"University of Pennsylvania","biomarkers":" BRCA1 • BRCA2","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation","tags":["BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e INO-5401 • rocakinogene sifuplasmid (INO-9012)"],"overall_status":"Recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 04/20/2021","start_date":" 04/20/2021","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-10-23"},{"id":"3d49c2e9-c873-459f-87ad-3ce24139ce28","acronym":"","url":"https://clinicaltrials.gov/study/NCT05603559","created_at":"2022-11-02T14:56:59.974Z","updated_at":"2024-07-02T16:35:32.151Z","phase":"Phase 1","brief_title":"177Lu-P17-087/177Lu-P17-088 in Patients With Metastatic Castration-resistant Prostate Cancer","source_id_and_acronym":"NCT05603559","lead_sponsor":"Peking Union Medical College Hospital","biomarkers":" FOLH1","pipe":" | ","alterations":" FOLH1 expression • FOLH1 overexpression","tags":["FOLH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FOLH1 expression • FOLH1 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 177Lu-P17-087 • 177Lu-P17-088"],"overall_status":"Completed","enrollment":" Enrollment 9","initiation":"Initiation: 01/01/2023","start_date":" 01/01/2023","primary_txt":" Primary completion: 09/05/2023","primary_completion_date":" 09/05/2023","study_txt":" Completion: 10/04/2023","study_completion_date":" 10/04/2023","last_update_posted":"2023-10-23"},{"id":"1b36b4ee-0095-44fb-b7a3-0681f98a1eb6","acronym":"ACTION","url":"https://clinicaltrials.gov/study/NCT05567770","created_at":"2022-10-05T12:55:59.042Z","updated_at":"2024-07-02T16:35:39.145Z","phase":"Phase 1","brief_title":"ACTInium-J591 Radionuclide Therapy in PSMA-Detected Metastatic HOrmone-Sensitive Recurrent Prostate CaNcer","source_id_and_acronym":"NCT05567770 - ACTION","lead_sponsor":"Weill Medical College of Cornell University","biomarkers":" FOLH1","pipe":" | ","alterations":" FOLH1 expression","tags":["FOLH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FOLH1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ac-225 rosopatamab tetraxetan (CONV01-α)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 12/01/2023","start_date":" 12/01/2023","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 01/01/2030","study_completion_date":" 01/01/2030","last_update_posted":"2023-08-24"},{"id":"9cbbdb17-3c67-4f8e-b5b1-c043d0ec52f1","acronym":"","url":"https://clinicaltrials.gov/study/NCT05613738","created_at":"2022-11-14T15:57:13.650Z","updated_at":"2024-07-02T16:36:00.556Z","phase":"","brief_title":"177Lu-PSMA-EB-01 in Patients With Metastatic Castration-resistant Prostate Cancer","source_id_and_acronym":"NCT05613738","lead_sponsor":"Peking Union Medical College Hospital","biomarkers":" FOLH1","pipe":" | ","alterations":" FOLH1 expression • FOLH1 overexpression","tags":["FOLH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FOLH1 expression • FOLH1 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 177Lu-LNC1003"],"overall_status":"Recruiting","enrollment":" Enrollment 9","initiation":"Initiation: 11/23/2022","start_date":" 11/23/2022","primary_txt":" Primary completion: 06/30/2023","primary_completion_date":" 06/30/2023","study_txt":" Completion: 11/15/2023","study_completion_date":" 11/15/2023","last_update_posted":"2022-11-11"},{"id":"ff68ee87-5cf9-4a0a-ac3b-71e15898e51d","acronym":"","url":"https://clinicaltrials.gov/study/NCT03692663","created_at":"2022-08-01T19:03:33.391Z","updated_at":"2024-07-02T16:36:06.382Z","phase":"Phase 1","brief_title":"Study of Anti-PSMA CAR NK Cell (TABP EIC) in Metastatic Castration-Resistant Prostate Cancer","source_id_and_acronym":"NCT03692663","lead_sponsor":"Allife Medical Science and Technology Co., Ltd.","biomarkers":" NCAM1","pipe":" | ","alterations":" FOLH1 expression","tags":["NCAM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FOLH1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • ALF501"],"overall_status":"Recruiting","enrollment":" Enrollment 9","initiation":"Initiation: 12/01/2018","start_date":" 12/01/2018","primary_txt":" Primary completion: 06/01/2023","primary_completion_date":" 06/01/2023","study_txt":" Completion: 06/01/2024","study_completion_date":" 06/01/2024","last_update_posted":"2022-08-01"},{"id":"024afde8-35f7-422f-a157-f42ce2f8352a","acronym":"","url":"https://clinicaltrials.gov/study/NCT03780075","created_at":"2021-01-19T17:18:08.502Z","updated_at":"2024-07-02T16:36:10.526Z","phase":"Phase 1","brief_title":"Lu177-EB-PSMA617 Radionuclide Treatment in Patients With Metastatic Castration-resistant Prostate Cancer","source_id_and_acronym":"NCT03780075","lead_sponsor":"Peking Union Medical College Hospital","biomarkers":" FOLH1","pipe":" | ","alterations":" FOLH1 expression • FOLH1 overexpression","tags":["FOLH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FOLH1 expression • FOLH1 overexpression"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 04/15/2018","start_date":" 04/15/2018","primary_txt":" Primary completion: 09/01/2020","primary_completion_date":" 09/01/2020","study_txt":" Completion: 12/01/2022","study_completion_date":" 12/01/2022","last_update_posted":"2022-05-12"},{"id":"e82d918b-6cc4-42ac-9711-92f01b350bee","acronym":"","url":"https://clinicaltrials.gov/study/NCT03403595","created_at":"2021-01-25T07:52:39.275Z","updated_at":"2024-07-02T16:37:14.724Z","phase":"Phase 1","brief_title":"177Lu-EB-PSMA617 in Patients With Metastatic Castration-resistant Prostate Cancer","source_id_and_acronym":"NCT03403595","lead_sponsor":"Peking Union Medical College Hospital","biomarkers":" FOLH1","pipe":" | ","alterations":" FOLH1 expression • FOLH1 overexpression","tags":["FOLH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FOLH1 expression • FOLH1 overexpression"],"overall_status":"Unknown status","enrollment":" Enrollment 30","initiation":"Initiation: 12/01/2017","start_date":" 12/01/2017","primary_txt":" Primary completion: 12/01/2018","primary_completion_date":" 12/01/2018","study_txt":" Completion: 12/01/2018","study_completion_date":" 12/01/2018","last_update_posted":"2018-01-18"},{"id":"7e38eb9d-5aae-4a5a-9e6d-998c32e68abe","acronym":"","url":"https://clinicaltrials.gov/study/NCT02607553","created_at":"2021-01-19T11:19:14.855Z","updated_at":"2024-07-02T16:37:25.084Z","phase":"Phase 2","brief_title":"Safety and Activity of G-202 in Patients With Clear Cell Renal Cell Carcinoma That Expresses PSMA","source_id_and_acronym":"NCT02607553","lead_sponsor":"GenSpera, Inc.","biomarkers":" FOLH1","pipe":" | ","alterations":" FOLH1 expression","tags":["FOLH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FOLH1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e mipsagargin (G-202)"],"overall_status":"Completed","enrollment":" Enrollment 2","initiation":"Initiation: 06/01/2016","start_date":" 06/01/2016","primary_txt":" Primary completion: 12/01/2016","primary_completion_date":" 12/01/2016","study_txt":" Completion: 02/01/2017","study_completion_date":" 02/01/2017","last_update_posted":"2017-02-24"},{"id":"b45c95c1-91da-4ed1-82bd-d94f9d53ddec","acronym":"","url":"https://clinicaltrials.gov/study/NCT02283320","created_at":"2021-01-18T10:45:27.234Z","updated_at":"2024-07-02T16:37:32.711Z","phase":"Phase 2","brief_title":"A Study of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) as Second-line Therapy for Patients With KRAS Positive or Squamous Cell Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT02283320","lead_sponsor":"BIND Therapeutics","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • PSMA-targeted docetaxel (BIND-014)"],"overall_status":"Completed","enrollment":" Enrollment 69","initiation":"Initiation: 09/01/2014","start_date":" 09/01/2014","primary_txt":" Primary completion: 04/01/2016","primary_completion_date":" 04/01/2016","study_txt":" Completion: 04/01/2016","study_completion_date":" 04/01/2016","last_update_posted":"2016-04-18"}]